A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

LA CAB for PrEP shows high effectiveness and persistence among Black cisgender and transgender women in the United States.

Black gay men face major PrEP access gaps due to cost, stigma, mistrust, and provider silence—despite high HIV impact; programs in cities/states show ways to close disparities.

Doxycycline PEP uptake after STI diagnosis varies by region and is most frequent among US male veterans on PrEP or living with HIV.

Uganda has received its first consignment of Lenacapavir, a long-acting HIV prevention injection administered twice a year, ...

HIV pre-exposure prophylaxis (PrEP) is an effective and safe intervention for individuals with behaviors that are considered high risk for acquiring HIV infection. Despite the success of this ...

The PrEP Access and Coverage Act would require all private and public insurance plans to cover pre-exposure prophylaxis (PrEP) for HIV prevention and related services with no out-of-pocket costs and ...

Pre-exposure prophylaxis (PrEP) is a drug regimen recommended for anyone at high risk of getting HIV to prevent them from being infected. Little research exists on how state-level policies might be ...

The Global Fund has committed an additional Sh256 million($2 million) to support Kenya’s rollout of the long-acting HIV preventioninjection, Lenacapavir, officials announced during the national launch ...

Executive actions in 2025 produced a 90-day freeze and stop orders; waivers incompletely restored services, with notable gaps in PrEP access for nonpregnant, nonbreastfeeding individuals. New research ...